News | July 26, 2024
Piramal Pharma Q1 FY25 net loss narrows
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
The company is planning to expand its plant capacity in in Vapi
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Laurus Labs receives EIR from USFDA for API facilities
The facility was inspected from May 7 to May 17, 2024
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
There was no observation related to data integrity reported
Subscribe To Our Newsletter & Stay Updated
